Revenue segments as reported by the company.

Women’s Health

Biosimilars

Established Brands

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Acquired in-process research and development and milestones

Interest expense

Exchange losses (gains)

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Organon & Co

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organon & Co reports strong Q4 earnings, eyes growth opportunities

Organon & Co's Q4 2022 earnings call highlighted robust financial performance, strategic initiatives in key segments, and a positive outlook for future growth. Despite challenges in China and market dynamics, the company remains focused on leveraging its strengths, addressing challenges, and capitalizing on growth opportunities to drive shareholder value and portfolio expansion.

Organon & Co reports solid Q1 performance and eyes growth opportunities

Organon & Co's Q1 2023 performance reflects revenue growth, margin improvement, and strategic investments in key franchises and medical devices.
The company's strengths lie in financial discipline, strong segment performance, and growth opportunities in fertility markets and biosimilars.
Challenges include inflationary pressures, competitive pricing scenarios, and the need to address loss of exclusivity and pricing dynamics.
Opportunities exist in expanding market presence in Asia Pacific, launching new products, and focusing on sustainable growth through financial prudence.

Organon & Co reports solid Q2 earnings, eyes growth opportunities

Organon & Co's Q2 2023 performance showed revenue growth, margin improvement, and strategic focus on key business segments.
Strengths in product differentiation, market positioning, and growth drivers position the company for continued success.
Challenges in revenue drivers, market expansion, and financial strategy require strategic adjustments for sustained growth.
Opportunities in Women's Health, biosimilar portfolio, and market penetration strategies offer avenues for future growth and market leadership.

Organon reports mixed Q3 results, eyes biosimilar growth opportunities

Organon's Q3 performance showed mixed results with challenges in women's health and biosimilar uptake, but stable growth in established brands.
The company is focusing on cost efficiency, portfolio optimization, and market expansion in biosimilars for future revenue growth.
Despite near-term challenges, Organon remains optimistic about its financial outlook, especially with opportunities in biosimilars and market expansion strategies.
Strategic shifts towards retail sector in China and product optimization are key focus areas for sustained growth and profitability.

Organon & Co reports solid Q4 earnings, eyes strategic growth

Organon's Q4 2023 earnings call showcased strong financials, strategic partnerships, and a focus on cost management. The company aims for low single-digit revenue growth in 2024 and $1 billion in free cash flow.

Organon & Co reports strong Q1 performance, eyes biosimilar growth

Organon & Co's Q1 2024 showcased robust revenue growth and strategic financial planning
Challenges include flat global fertility business and cautious outlook due to foreign exchange dynamics
Opportunities lie in expanding biosimilar market, margin expansion, and transformative deals

Organon & Co reports solid Q2 earnings, eyes franchise growth

Organon & Co's Q2 2024 performance reflects a mix of solid revenue growth and margin stability.
While facing challenges in certain regions and franchise segments, the company maintains a focus on growth.
Strategic opportunities lie in expanding key franchises, regulatory milestones, and operational efficiency.
Overall, Organon & Co remains optimistic about sustained revenue growth and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoint.

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Oversea-Chinese Banking Corp Ltd

Southside Bancshares

Now may be an ideal time to buy these lower-risk, high-income stocks especially as markets start to digest hot inflationary data.

Markets Dip but it's Time to Buy These Low-Risk High-Income Stocks

Conagra Brands

Despegar.com

As March begins, the stock market promises a high playground to turn modest investments into massive wealth. Amidst this enthusiasm, three top stock picks for rally stand out as pillars of opportunity.

Turn $500 into a Fortune: 3 Top Stock Picks for March's Million-Dollar Rally

Evolution Petroleum

Heidrick & Struggles International

Some stocks glitter more prominently than others in the vast investment pool. However, amidst the popularity of high-profile names, a line of overlooked stocks exists, steadily leading to a market edge.

Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market

Brookline Bancorp

Patria Investments

Now looks like a good time to buy these highly ranked stocks with earnings estimate revisions likely to keep ticking up after their favorable Q4 results which makes their high dividend yields and low beta ratios more attractive.

Don't Overlook These Low-Risk High-Dividend Yielding Stocks

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary.

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

Organon & Co. (OGN) Q4 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023.

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will release fourth quarter and full year 2023 financial results on February 15, 2024, and hold a webcast and conference call at 8:30 AM EST.

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024

Organon & Co (OGN) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's regular dividend to remain primary capital allocation priority. Organon affirms 2023 guidance and provides 2024 outlook.

Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook

Organon, a pharmaceutical company, has a diverse portfolio of products in women's health and biosimilars. The company has faced challenges in its women's health segment but expects a turnaround in its top-selling drug and growth in the fertility business this year. Organon is focused on deleveraging its balance sheet and offers a high dividend yield while trading at a valuation far below that of health sector peers.

Organon: What I'm Looking For In This 8% Yield In 2024

Citizens Financial Group

Civitas Resources

Comerica

Columbia Banking System

Clearway Energy

Guess?

Lincoln National

AT&T

Uniti Group

Whirlpool

Investors have different approaches to stock dividends. Some have no interest in current income and would prefer companies to focus on growing their businesses, rather than distributing cash to shareholders.

11 dividend stocks with high yields expected to be well supported in 2024 per strict criteria

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference, Tuesday January 9.

Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference

Organon's stock has declined 32% since September, making it one of the worst performers in healthcare. The company reported mixed financial results, with 1% growth in product sales and a decline in total revenue. Organon's biggest challenge is debt reduction, but its strategic focus on cost efficiency and debt reduction could lead to significant returns.

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued

Eli Lilly

JERSEY CITY, N.J.--(BUSINESS WIRE) Organon becomes the sole distributor and promoter of Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe.

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Albemarle

Amazon

Alibaba

Bilibili

Bristol-Myers

Farfetch

JD.com

KeyCorp

Lucid Group

Medtronic

ModivCare

Nikola

NetEase

Pinduoduo Inc - ADR

Pfizer

Insulet

PayPal

Sibanye Stillwater

Charles Schwab

Seagen

Block

Tencent Holdings Limited

Tandem Diabetes Care

VinFast Auto Ltd

Investors should consider tax-loss selling before December ends to offset capital gains. Two characteristics to consider for selling stocks are stocks bought at a higher price and broken companies with weak long-term prospects. Stock grades, sentiment, and fundamentals assessed.

8 Tax-Loss Sell Alerts For December

Organon is a global healthcare company focused on women's health, with a diverse portfolio of prescription therapies and medical devices. OGN stock has been on a downward trend due to declining sales and excessive debt on the balance sheet. Despite challenges, Organon saw product sales grow 1% and achieved stability in its Established Brands division.

Organon: It's Darkest Before The Dawn

Organon & Co (NYSE:OGN ) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 11:00 AM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler David Amsellem Okay. Good morning, everyone, and let's get started.

Organon & Co (OGN) Piper Sandler 35th Annual Healthcare Conference (Transcript)

It has been over two years since Organon spun off from Merck. Lack of growth and deteriorating financials haven't given investors much of a reason to be bullish thus far.

Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?

Avid Bioservices

DISH Network

Ligand Pharmaceuticals

Enviri Corp

Arcus Biosciences

REGENXBIO

Semtech

Vir Biotechnology

ViaSat

Xencor

It's been all about the biggest of the big S&P 500 stocks all year. But now, investors are starting to look for big gains from small stocks.

It's Small Stocks' Time To Rally — Analysts Like These 11 Best

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 11:00 a.m. EST. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentat.

Organon To Present at the Piper Sandler 35th Annual Healthcare Conference

News for Organon & Co Stock (OGN)